{"result": "(\"entity\"<|>TOLVAPTÁN<|>ORGANIZATION<|>Tolvaptán is a medication used in the treatment of conditions like SIADH, aimed at managing serum sodium levels.)\n##\n(\"entity\"<|>SIADH<|>EVENT<|>Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) is a condition that leads to hyponatremia due to excess water retention.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>ORGANIZATION<|>Artificial nutrition refers to the provision of nutrients through enteral or parenteral means, often used in patients unable to eat normally.)\n##\n(\"entity\"<|>NE<|>ORGANIZATION<|>Nutrition Enteral (NE) is a method of delivering nutrition directly to the gastrointestinal tract.)\n##\n(\"entity\"<|>NP<|>ORGANIZATION<|>Nutrition Parenteral (NP) is a method of delivering nutrients directly into the bloodstream, bypassing the gastrointestinal tract.)\n##\n(\"entity\"<|>HIDROCORTISONA<|>ORGANIZATION<|>Hydrocortisone is a corticosteroid medication used to treat various conditions, including adrenal insufficiency.)\n##\n(\"entity\"<|>FUROSEMIDA<|>ORGANIZATION<|>Furosemide is a diuretic medication used to treat fluid retention and high blood pressure.)\n##\n(\"entity\"<|>SRAA<|>ORGANIZATION<|>The Renin-Angiotensin-Aldosterone System (SRAA) is a hormone system that regulates blood pressure and fluid balance.)\n##\n(\"entity\"<|>ALBUMINA<|>ORGANIZATION<|>Albumin is a protein in blood plasma that helps maintain oncotic pressure and is used in various medical treatments.)\n##\n(\"relationship\"<|>TOLVAPTÁN<|>SIADH<|>Tolvaptán is used to treat SIADH by managing serum sodium levels<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>NE<|>Nutrition Enteral is a form of artificial nutrition<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>NP<|>Nutrition Parenteral is another form of artificial nutrition<|>7)\n##\n(\"relationship\"<|>HIDROCORTISONA<|>SIADH<|>Hydrocortisone may be administered in cases of adrenal insufficiency related to SIADH<|>6)\n##\n(\"relationship\"<|>FUROSEMIDA<|>SIADH<|>Furosemide is used in the management of fluid retention in patients with SIADH<|>6)\n##\n(\"relationship\"<|>SRAA<|>FUROSEMIDA<|>Furosemide acts on the Renin-Angiotensin-Aldosterone System to help manage blood pressure<|>5)\n##\n(\"relationship\"<|>ALBUMINA<|>NUTRICIÓN ARTIFICIAL<|>Albumin may be used in conjunction with artificial nutrition to manage fluid balance<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: mmol/l\n                                                              (misma dosis que el día previo)\n\n\n\n                 Figura 4.     Protocolo de inicio de tolvaptán en pacientes con SIADH y nutrición artificial.\n                 TV: tolvaptán, NaS: natremia sérica, SG: suero glucosado, DDAVP: desmopresina.\n                 Adaptado del algoritmo multidisplinar español de manejo del SIADH. Nefrología, 2014.\n\n\n\n                                                                                  REPONER LA VOLEMIA\n                                                      Nutrición enteral (NE)                        Nutrición parenteral (NP)\n                            HipoNa                        SFS al 0,9% iv                            Opción A: SFS al 0,9% iv\n                       HIPO‐volémica                                                            Opción B: ↑ Na y volumen de NP\n                                                            Además, en caso de: Diuréticos (retirar), ISP 1ª (hidrocortisona),\n                                                                      Déficit aislado de aldosterona (fludrocortisona)\n\n\n\n                                                           DISMINUIR EL APORTE DE LÍQUIDOS + Na (mínimo 136 mEq/día)\n                            HipoNa                  NE : Fórmula hipercalórica            NP : Concentrar la fórmula y la medicación iv\n                         EU‐volémica                ↑↑ fisiológica ADH                            SIADH                      ISP 2ª (déficit\n                                                      Dolor (analgesia)               OsmU > 350: Furosemida (F)                de ACTH)\n                                                   Náusea (antihemético)            No respuesta a F: Tolvaptán (si es       Hidrocortisona\n                                                                                                 posible)\n\n\n\n                                                           DISMINUIR EL APORTE DE LÍQUIDOS + Na (mínimo 136 mEq/día)\n                            HipoNa                                                     FUROSEMIDA\n                      HIPER‐volémica                            OTROS: Bloqueo SRAA, paracentesis y albúmina (ascitis)\n                                                    NE: Fórmula hipercalórica             NP: Concentrar la fórmula y la medicación iv\n\n\n\n                 Figura 5.     Tratamiento de la hiponatremia no grave ajustado al tipo y etiología de la\n                 misma, durante la administración de la nutrición artificial. SFS: suero fisiológico\n                 salino; ISP: insuficiencia suprarrenal primaria; Na: sodio; SRRA: sistema renina\n                 angiotensina aldosterona.\n\n\n\n    ria, insuficiencia cardiaca aguda y cirrosis con                                             suprarrenal primaria y fludrocortisona en algu-\n    ascitis.                                                                                     nos casos de hipoaldosteronismo aislado.\n4)  Tratamiento ajustado al tipo y etiología de la HipoNa:                                   •   Hipervolémica. Disminuir el aporte de líquidos\n                                                                                                 (fórmula hipercalórica en NE, concentrar la medi-\n    •   Hipovolémica. Reponer la volemia con solución                                            cación intravenosa y la fórmula de NP), adminis-\n        salina isotónica. Además de retirar el diurético,                                        trar furosemida y un aporte mínimo de sodio de\n        administrar hidrocortisona en la insuficiencia                                           136 mEq/día para garantizar su acción terapéuti-\n---\n 814      BLOQUE: SOPORTE NUTRICIONAL AVANZADO\n\n\n\n          ca. Valorar otras terapias: bloqueo del SRAA y en                 on serum sodium, potassium, and glucose levels. J\n          pacientes con ascitis (paracentesis y albúmina).                  Nurs Scholarsh. 2005; 37(2):141-7.\n       •  Euvolémica. Disminución de los líquidos e incre-             11.  Clayton JA, Le Jeune IR, Hall IP. Severe hyponatre-\n          mento del aporte de sodio, al igual que en la                     mia in medical in-patients: aetiology,assessment\n          HipoNa hipervolémica. En la elevación de la ADH                   and outcome. QJM. 2006; 99:505.\n          por dolor y náusea, administrar antieméticos y               12.  Gill GV, Huda MSB, Wile D, Boyd A, Skagen K,\n          analgesia. Así como hidrocortisona en los pa-                     Watson ID, et al. Characterisstics and outcome of\n          cientes con insuficiencia suprarrenal secundaria                  severe hyponatremia- a case control study. Clinical\n          y furosemida en los pacientes con SIADH y os-                     Endocrinol (Oxf). 2006; 65:246-9.\n          molalidad urinaria > 350 mOsmol/kg. En los                   13.  Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD.\n          pacientes con SIADH, si a pesar de las medidas                    Mortality and Serum Sodium: Do Patients Die from\n          previas persiste la hiponatremia, valorar el uso                  or with Hy\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}